Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Niaspan approved in France

Oct. 19, 2004

New GLP-1 analogues and their use covered by SCRAS patent

Oct. 19, 2004

Update on the pharmacokinetic profile of a transdermal PTH formulation

Oct. 18, 2004

Bone turnover has no effect on the benefits of teriparatide in women with osteoporosis

Oct. 18, 2004

Pivotal PolyHeme study cleared to continue

Oct. 18, 2004

IND submission for Syrrx-designed DPP IV inhibitor for diabetes

Oct. 18, 2004

Novel PPAR agonists and their use described by Pfizer researchers

Oct. 18, 2004

Novel vasopressin V1a receptor antagonists and their use in dysmenorrhea

Oct. 18, 2004

Pharmacokinetic profile of novel bone resorption inhibitor

Oct. 18, 2004

Long-term octreotide restores gonadal function in male patients with acromegaly

Oct. 15, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...
Recludix’s first-in-class STAT6 inhibitor shows efficacy in atopic dermatitis
BioWorld Science
Researchers from Recludix Pharma Inc. reported preclinical efficacy data on REX-8756 (SAR-448755), a first-in-class orthosteric STAT6 inhibitor in models of...